Technical Analysis for ATRA - Atara Biotherapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -4.06% | |
Narrow Range Bar | Range Contraction | -4.06% |
Alert | Time |
---|---|
Down 3% | about 12 hours ago |
Fell Below Previous Day's Low | about 12 hours ago |
Down 2 % | about 12 hours ago |
Down 1% | about 12 hours ago |
Rose Above Lower Bollinger Band | about 13 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/26/2024
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.17 |
52 Week Low | 0.1986 |
Average Volume | 3,500,991 |
200-Day Moving Average | 1.23 |
50-Day Moving Average | 0.73 |
20-Day Moving Average | 0.73 |
10-Day Moving Average | 0.68 |
Average True Range | 0.09 |
RSI (14) | 37.11 |
ADX | 25.86 |
+DI | 22.40 |
-DI | 19.23 |
Chandelier Exit (Long, 3 ATRs) | 0.68 |
Chandelier Exit (Short, 3 ATRs) | 0.85 |
Upper Bollinger Bands | 0.85 |
Lower Bollinger Band | 0.60 |
Percent B (%b) | -0.02 |
BandWidth | 34.65 |
MACD Line | -0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0177 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.66 | ||||
Resistance 3 (R3) | 0.67 | 0.65 | 0.65 | ||
Resistance 2 (R2) | 0.65 | 0.63 | 0.65 | 0.65 | |
Resistance 1 (R1) | 0.62 | 0.62 | 0.62 | 0.62 | 0.64 |
Pivot Point | 0.61 | 0.61 | 0.60 | 0.60 | 0.61 |
Support 1 (S1) | 0.58 | 0.59 | 0.57 | 0.57 | 0.55 |
Support 2 (S2) | 0.56 | 0.58 | 0.56 | 0.54 | |
Support 3 (S3) | 0.53 | 0.56 | 0.54 | ||
Support 4 (S4) | 0.53 |